CoChat

A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors

Fine, Howard A., Kim, Lyndon, Albert, Paul S., Duic, J. Paul, Ma, Hilary, Zhang, Wei, Tohnya, Tanyifor, Figg, William D., Royce, Cheryl · 2007 · Clinical Cancer Research
Cited by 66

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. Experimental Design: A phase I interpatient dose escalation trial of lenalidomide in patients with recurrent primary central nervous system tumors was conducted. Results: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m2, with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months. Conclusion: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m2. Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1546

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 66

Metadata

Authors
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T., Figg, W. D., & Royce, C.
Venue
Clinical Cancer Research
Published
2007-12-01
Volume
13
Issue
23
Pages
7101-7106
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2112757377
Cited by
66
References
5
FWCI
2.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1546
The paper
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T., Figg, W. D., & Royce, C. (2007). A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.